The Association between Genetic Variations of CHI3L1, Levels of the Encoded Glycoprotein YKL-40 and the Lipid Profile in a Danish Population

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Thomsen, Stine Brinkløv ^a   Rathcke, Camilla Noelle ^a   Skaaby, Tea ^a   Linneberg, Allan ^a   Vestergaard, Henrik ^a,b  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLYCOPROTEIN; GLYCOPROTEIN YKL 40; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHI3L1 GENE; CHOLESTEROL BLOOD LEVEL; DENMARK; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROTEIN BLOOD LEVEL; REPLICATION STUDY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOKINES; ADULT; AGED; DENMARK; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; LECTINS; LIPIDS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TRIGLYCERIDES;

EID: 84867183851     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047094     Document Type: Article

References (52)

1. Goldberg IJ, Eckel RH, McPherson R, (2011) Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol 31: 1716-1725.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, et al. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364: 937-952.
3. Pradhan AD, Skerrett PJ, Manson JE, (2002) Obesity, diabetes, and coronary risk in women. J Cardiovasc Risk 9: 323-330.
4. Wilson PW, Anderson KM, Castelli WP, (1991) Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham offspring study. Am J Med 90: 11-16.
5. Vinik AI, (2005) The metabolic basis of atherogenic dyslipidemia. Clin Cornerstone 7: 27-35.
6. Maury E, Brichard SM, (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314: 1-16.
7. Boden G, (2011) Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 18: 139-143.
8. Pickup JC, (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27: 813-823.
9. Cancello R, Clement K, (2006) Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG 113: 1141-1147.
10. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, et al. (2006) Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91: 2906-2912.
11. Rathcke CN, Vestergaard H, (2009) YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 8: 61.
12. Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, et al. (2008) YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J 42: 295-302.
13. Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H, (2009) YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 32: 323-328.
14. Rathcke CN, Johansen JS, Vestergaard H, (2006) YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 55: 53-59.
15. Mygind ND, Harutyunyan MJ, Mathiasen AB, Ripa RS, Thune JJ, et al. (2011) The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflamm Res 60: 281-287.
16. Hempen M, Kopp HP, Elhenicky M, Hobaus C, Brix JM, et al. (2009) YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes Surg 19: 1557-1563.
17. Nielsen AR, Erikstrup C, Johansen JS, Fischer CP, Plomgaard P, et al. (2008) Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 57: 3078-3082.
18. Nielsen KR, Steffensen R, Boegsted M, Baech J, Lundbye-Christensen S, et al. (2011) Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arthritis Res Ther 13: R109.
19. Zheng JL, Lu L, Hu J, Zhang RY, Zhang Q, et al. (2011) Genetic polymorphisms in chitinase 3-like 1 (CHI3L1) are associated with circulating YKL-40 levels, but not with angiographic coronary artery disease in a Chinese population. Cytokine 54: 51-55.
20. Ober C, Tan Z, Sun Y, Possick JD, Pan L, et al. (2008) Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 358: 1682-1691.
21. Kruit A, Grutters JC, Ruven HJ, van Moorsel CC, van den Bosch JM, (2007) A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker. Respir Med 101: 1563-1571.
22. Lee H, Kang R, Jee SH, Yoon Y, (2010) A promoter polymorphism-2122C>T of CHI3L1 is associated with serum low density lipoprotein cholesterol level in Korean subjects. Clin Biochem 43: 1195-1200.
23. Rosenstock SJ, Jorgensen T, (1995) Prevalence and incidence of peptic ulcer disease in a Danish County-a prospective cohort study. Gut 36: 819-824.
24. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, et al. (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268: 296-308.
25. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, et al. (2009) New risk markers may change the HeartScore risk classification significantly in one-fifth of the population. J Hum Hypertens 23: 105-112.
26. [Anonymous] (2008) WHO:Waist circumference and Waist-hip ratio. A report of a WHO expert consultation, Geneva, december 8-11.
27. Ambye L, Rasmussen S, Fenger M, Jorgensen T, Borch-Johnsen K, et al. (2005) Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) gene in Danish subjects with the metabolic syndrome. Diabetes Res Clin Pract 67: 175-179.
28. Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, et al. (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 10: 377-386.
29. Rathcke CN, Holmkvist J, Husmoen LL, Hansen T, Pedersen O, et al. (2009) Association of polymorphisms of the CHI3L1 gene with asthma and atopy: a populations-based study of 6514 Danish adults. PLoS One 4: e6106.
30. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, et al. (2005) Efficiency and power in genetic association studies. Nat Genet 37: 1217-1223.
31. Rousset F, (2008) genepop'007: a complete re-implementation of the genepop software for Windows and Linux. Mol Ecol Resour 8: 103-106.
32. Hubert HB, Feinleib M, McNamara PM, Castelli WP, (1983) Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67: 968-977.
33. Lavie CJ, Milani RV, (2003) Obesity and cardiovascular disease: the hippocrates paradox? J Am Coll Cardiol 42: 677-679.
34. Erridge C, Attina T, Spickett CM, Webb DJ, (2007) A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86: 1286-1292.
35. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761-1772.
36. Ji C, Chen X, Gao C, Jiao L, Wang J, et al. (2011) IL-6 induces lipolysis and mitochondrial dysfunction, but does not affect insulin-mediated glucose transport in 3T3-L1 adipocytes. J Bioenerg Biomembr 43: 367-375.
37. Grisouard J, Bouillet E, Timper K, Radimerski T, Dembinski K, et al. (2012) Both inflammatory and classical lipolytic pathways are involved in lipopolysaccharide-induced lipolysis in human adipocytes. Innate Immun 18: 25-34.
38. Recklies AD, White C, Ling H, (2002) The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 365: 119-126.
39. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ, (1999) Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250: 168-173.
40. Rathcke CN, Vestergaard H, (2006) YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res 55: 221-227.
41. Boot RG, van Achterberg TA, van Aken BE, Renkema GH, Jacobs MJ, et al. (1999) Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 19: 687-694.
42. Krause SW, Kreutz M, Andreesen R, (1996) Differential effects of cell adherence on LPS-stimulated cytokine production by human monocytes and macrophages. Immunobiology 196: 522-534.
43. Kirkpatrick RB, Emery JG, Connor JR, Dodds R, Lysko PG, et al. (1997) Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp Cell Res 237: 46-54.
44. Michelsen AE, Rathcke CN, Skjelland M, Holm S, Ranheim T, et al. (2010) Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis 211: 589-595.
45. Kjaergaard AD, Bojesen SE, Johansen JS, Nordestgaard BG, (2010) Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol 68: 672-680.
46. Rondbjerg AK, Omerovic E, Vestergaard H, (2011) YKL-40 levels are independently associated with albuminuria in type 2 diabetes. Cardiovasc Diabetol 10: 54.
47. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S, (2007) Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 18: 391-396.
48. Brix JM, Hollerl F, Koppensteiner R, Schernthaner G, Schernthaner GH, (2011) YKL-40 in type 2 diabetic patients with different levels of albuminuria. Eur J Clin Invest 41: 589-596.
49. Catalan V, Gomez-Ambrosi J, Rodriguez A, Ramirez B, Rotellar F, et al. (2011) Increased circulating and visceral adipose tissue expression levels of YKL-40 in obesity-associated type 2 diabetes are related to inflammation: impact of conventional weight loss and gastric bypass. J Clin Endocrinol Metab 96: 200-209.
50. Cho HK, Shin G, Ryu SK, Jang Y, Day SP, et al. (2002) Regulation of small dense LDL concentration in Korean and Scottish men and women. Atherosclerosis 164: 187-193.
51. Kesteloot H, Lee CS, Park HM, Kegels C, Geboers J, et al. (1982) A comparative study of serum lipids between Belgium and Korea. Circulation 65: 795-799.
52. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, et al. (2007) Replicating genotype-phenotype associations. Nature 447: 655-660.